DelveInsight

The occurrence of acute myeloid leukemia (AML) keeps on increasing with age and mortality surpasses 90% if diagnosed after age of 65. Most cases emerge with no perceivable early side effects and patients generally give the intense intricacies of bone marrow failure. The beginning of such oinitial acute myeloid leuke...

Arming antibiotics with a vaccination-like immune response Harnessing the ability of the body’s immune system has already well-tried to be effective in treating cancer. Marcos Pires, Ph.D., a Lehigh associate professor of biochemistry performed a test on it. To make it worse, these microorganism perpetually evolv...

Fatty acid amide hydrolase (FAAH) belongs to the serine hydrolase family of enzymes. The identification of this enzyme was led by the discovery and characterization of fatty acid amides, including anandamide and oleamide, as a fundamental class of endogenous signaling molecules. FAAH serves as the major metabolic re...

Hepatic Encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-standing or chronic liver disorder are at high risk. The disease may also be triggered by bleeding in the digestive tract,...

NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) is a protein transcription factor that can orchestrate complex biological processes such as cell survival, cytokine production, inflammatory response and cellular responses. NF-κB is also involved in producing the synergistic immune responses. NF...

Idera's dermatomyositis drug missed primary endpoint in phase 2 Idera’s toll-like receptor (TLR) antagonist, IMO-8400, failed to meet its primary endpoint in a phase 2 trial carried on adults with dermatomyositis. Data has shown that the drug was meant to block TLR 7, 8 and 9 but failed to beat placebo in making a s...

Axovant rely on new gene therapy, Rise in Shares  Roivant Neuro Company has licensed Oxford Biomedica’s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson’s disease (PD). Spark Therapeutics’ Former CTO Fraser Wright, Ph.D has been hired as its new CTO. Axovant expects to stimulate a phase 1/2 dose escalation stu...

A group of researchers has recently discovered that an immune mechanism responsible in clearing bacterial infections may also be involved in causing Parkinson's disease. The study has identified the role of protein LRRK2 in tuberculosis, results have shown that it behaves similarly in Parkinson disease. This finding...

ImmusanT upgrading the management ahead of phase 2 celiac vaccine trial ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo’s SVP for internal medicine therapeutics, Ken Truitt, M.D., as its new chief medical officer. The management is also boosted with new VPs in program management and clinical oper...